Bleeding disorders
This presentation is the property of its rightful owner.
Sponsored Links
1 / 46

Bleeding Disorders PowerPoint PPT Presentation


  • 159 Views
  • Uploaded on
  • Presentation posted in: General

Bleeding Disorders. Meera Shreedhara 8/25/08. What is it?. A bleeding disorder is an acquired or inherited tendency to bleed excessively. Mechanisms of bleeding. Vascular Integrity Platelets Clotting factors Fibrinolysis Derangement of any of these factors can cause abnormal bleeding.

Download Presentation

Bleeding Disorders

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Bleeding disorders

Bleeding Disorders

Meera Shreedhara

8/25/08


What is it

What is it?

  • A bleeding disorder is an acquired or inherited tendency to bleed excessively


Mechanisms of bleeding

Mechanisms of bleeding

  • Vascular Integrity

  • Platelets

  • Clotting factors

  • Fibrinolysis

  • Derangement of any of these factors can cause abnormal bleeding


Key to diagnosis

Key to diagnosis

  • History

  • History

  • History


Bleeding history

Bleeding history

  • Epistaxis

  • Gingival hemorrhage

  • Mucosal Bleeding

  • Heavy Menses

  • Child birth

  • Easy bruisability

  • Bleeding following tooth extractions

  • Hematomas

  • Bleeding following surgery

  • Hemarthrosis


Medication history

Medication History

  • Aspirin

  • Warfarin

  • NSAIDS

  • B- Lactam antibiotics

  • Clopidogrel and other antiplatelet agents

  • Herbal medications.


Nutritional history

Nutritional history

  • Vit K deficiency

  • Vit C deficiency

  • Broad spectrum antibiotics


History

History

  • Should the pt undergo a limited or extensive workup?

  • Is this acquired or hereditary?

  • Is this likely a disorder of clotting factors,platelets, fibrinolysis or vWF?

  • Do medications or intercurrent illnesses play a role?

  • What is the immediate cause for which a workup is being done?


Hereditary

Hereditary

  • Deficiency of coagulation factors

    • Hemophilia

    • Fibrinogen deficiency

    • Von Willebrand disease

  • Platelet disorders

    • Glanzmann thrombasthenia

    • Bernard-Soulier syndrome

    • Platelet granule disorders

  • Fibrinolytic disorders

    • Alpha 2 antiplasmin deficiency

    • PAI 1 deficiency

  • Structural disorders

    • Hemorrhagic Telangiectasias

    • Ehler Danlos syndrome


Acquired

Acquired

  • Thrombocytopenis

  • Liver disease

  • Renal failure

  • Vit K deficiency

  • Acquired antibodies to coagulation factors

  • DIC

  • Drugs

  • Vascular


Lab testing

Lab testing

  • Platelet count

  • Bleeding time-Measure of the interaction of platelets with the blood vessel wall.

    • Thrombocytopenia (platelet count usually below 50,000/microL),

    • Qualitative platelet abnormalities (eg, uremia),

    • von Willebrand disease (VWD),

    • Vascular purpura,

    • Severe fibrinogen deficiency


Platelet function assay

Platelet function assay

  • Expose platelets within citrated whole blood to high shear (5,000 to 6,000/sec) within a capillary tube and monitor the drop in flow rate as the platelets form a hemostatic plug within the center of a membrane coated with collagen and either ADP or epinephrine

  • Abnormal closure times are an indication of platelet dysfunction, they are not specific for any disorder

  • The test is coagulation factor independent

  • PFA-100™ is more sensitive (>70 percent) than the bleeding time (20 to 30 percent) in detecting all subtypes of von Willebrand's disease (vWD)

  • Exception is type 2N vWD, in which the hemostatic defect resides in the Factor VIII binding site on vWF


Platelet function assay1

Platelet function assay

  • Collagen/epinephrine closure time (CEPI-CT)- Abnormal in Aspirin intake

  • Collagen/adenosine diphosphate (CADT-CT)-Normal in aspirin intake


Prothrombin time

Prothrombin time

  • Measure of the extrinsic pathway and common pathway

  • Bypasses the intrinsic pathway and uses thromboplastins to substitute for platelets

  • Within the combined pathway, factors VII, X, and prothrombin are vitamin-K dependent and are altered by warfarin


Prolonged pt

Prolonged PT

  • Vitamin K deficiency

  • Liver disease, which decreases the synthesis of both vitamin K-dependent and -independent clotting factors.

  • Deficiency or inhibition of factors VII, X, II (prothrombin), V, or fibrinogen

  • The infrequent antiphospholipid antibodies (lupus anticoagulant phenomenon) with antiprothrombin activity

  • Heparin does NOT prolong the PT


Bleeding disorders

aPTT

  • Measures the intrinsic and common pathways of coagulation

  • Uses partial thromboplastins; they are incapable of activating the extrinsic pathway

  • Prolonged in deficiency of, or an inhibitor to, any of the clotting factors except for factor VII

  • Prolonged in the presence of Lupus Anticoagulant.

  • Used to monitor heparin activity


Thrombin time

Thrombin time

  • Measure conversion of fibrinogen to fibrin monomers and the formation of initial clot by thrombin

  • Hypofibrinogenemia,

  • Dysfibrinogens

  • Increased fibrin split products

  • Heparin increases TT but not RT


Factor deficiencies inhibitors

Factor deficiencies/ inhibitors

  • A prolonged aPTT can be due to a deficiency (or absence) of a coagulation factor or the presence of a coagulation factor inhibitor

  • Mixing studies help differentiate this

  • Lupus anticoagulants can result in a prolonged aPTT that is not correctable by the addition of normal plasma

  • Overcome by adding excess platelet phospholipid (particularly a hexagonal phase phospholipid) or by assessing the diluted Russell's viper venom time


Fibrinolysis

Fibrinolysis

  • Fibrin and fibrinogen degradation products (FDP) are protein fragments resulting from the action of plasmin on fibrin or fibrinogen


Fibrinolysis1

Fibrinolysis

  • FDP assays do not differentiate between fibrin degradation products and fibrinogen degradation products

  • Fibrin D-dimers are degradation products of cross-linked fibrin

  • D-dimers specifically reflect fibrinolysis of cross-linked fibrin (ie, the fibrin clot) – so are more reliable indicators of thrombosis


Fibrinolysis2

Fibrinolysis

  • Assays for plasminogen,

  • Tissue plasminogen activator (t-PA),

  • Alpha-2 antiplasmin,

  • Plasminogen activator inhibitor-1 (PAI-1),

  • Thrombin-activatable fibrinolysis inhibitor (TAFI).


Normal pt and ptt

Normal PT and PTT

  • Thrombocytopenia

  • vWD

  • Factor 13 deficiency

  • Platelet dysfunction

  • Vascular purpuras

  • Psychogenic purpura


Normal pt and prolonged aptt

Normal PT and Prolonged aPTT

  • Hemophilia A

  • Hemophilia B

  • Factor XI deficiency

  • Factor VIII inhibitor

    • Malignancy,

    • Clonal lymphoproliferative disorders,

    • Pregnancy,

    • Rheumatologic disorders


Prolonged pt and normal aptt

Prolonged PT and normal aPTT

  • Factor VII deficiency

  • Warfarin therapy

  • Early liver disease

  • Early DIC


Prolonged pt and ptt

Prolonged PT and PTT

  • Vit K deficiency

  • Liver disease

  • Warfarin treatment

  • Acquired inhibitor to factor V

  • Factor X deficiency- seen in Amyloidosis

  • DIC


Acute promyelocytic leukemia

Acute Promyelocytic Leukemia

  • DIC is often seen at presentation or during treatment

  • Medical Emergency as Cerebral hemorrhage can occur in upto 4% of untreated pts

  • Promyelocytes seen on smear

  • Reciprocal translocation between the long arms of chromosomes 15 and 17, with the creation of a fusion gene, PML/RAR-alpha

  • Immediate initiation of ATRA induces de deifferentiation


Hemophilia

Hemophilia

  • Hemophilia A and B are X-linked recessive diseases

  • Severe disease <1 % factor activity,

  • Moderate disease- 1 to 5 %

  • Mild disease >5 %

  • The most common sites are into joints and muscles and from the gastrointestinal tract


Treatment

Treatment

  • The two components to therapy are treatment of active bleeding and inhibitor ablation via immune tolerance induction

  • Cryoprecipitate has high levels of factor VIII

  • Porcine Factor VIII

  • Recombinant human Factor VIII

  • The choice of factor VIII product usually is based upon safety, purity, and cost.


Dosing

Dosing

  • One international unit (IU) of clotting factor is that amount present in 1 mL of pooled normal plasma

  • Dose of F VIII (IU) = Weight (kg) x (Desired % increase) x 0.5

  • Depends on the clinical indication and the presence of inhibitors


Von willebrand s disease

von Willebrand’s disease

  • Most common of the inherited bleeding disorders

  • In 1926, Erik von Willebrand described the first patient with the disease

  • Von Willebrand factor (VWF) binds to both platelets and endothelial components, forming an adhesive bridge between platelets and vascular subendothelial structures and between adjacent platelets at sites of endothelial injury


Acquired von willebrand s disease

Malignant diseases

Monoclonal gammopathy of unknown significance

Multiple Myeloma

Non-Hodgkin's lymphoma

Chronic lymphocytic leukemia

Waldenstrom's macroglobulinemia

Essential thrombocythemiaPolycythemia vera

Chronic myelogenous leukemia

Wilms tumor

Other carcinomas

Immunologic disorders

Systemic lupus erythematosus

Other autoimmune diseases

Other disorders

Hypothyroidism

Ventricular septal defect

Aortic stenosis

Mitral valve prolapse

Gastrointestinal angiodyplasia

Uremia

Hemoglobinopathies

Drugs and other agents

Valproic acid

Antibiotics

Acquired von Willebrand’s disease


Treatment1

Treatment

  • DDAVP

  • Replacement of vWF

  • EACA

  • Tranexamic acid

  • Recombinant factor 7


Its better to bleed than clot

Its better to bleed than clot!


Therapies other than factor replacement

Therapies other than factor replacement

  • DDAVP

  • EACA

  • Tranexamic Acid

  • Factor 7 inhibitor- Novoseven


Liver disease vs dic

Liver disease Vs DIC

  • Low factor V levels can be used as evidence for either reduced hepatic synthetic function or increased consumption, as in DIC

  • Factor VIII is not manufactured by hepatocytes; factor VIII levels are usually normal or increased in liver disease


  • Login